Yuanbing Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanbing Wu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Isidoro Metón
Secció de Bioquímica i Biologia Molecular, Departament de Bioquímica i Fisiologia, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Joan XXIII 27-31, 08028 Barcelona, Spain
5 shared publications - Ania Rashidpour
Secció de Bioquímica i Biologia Molecular, Departament de Bioquímica i Fisiologia, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Joan XXIII 27-31, 08028 Barcelona, Spain
4 shared publications - María Pilar Almajano
Departament d’Enginyeria Química, Universitat Politècnica de Catalunya, Diagonal 647, 08028 Barcelona, Spain
3 shared publications - Anna Fàbregas
Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Joan XXIII 27-31, 08028 Barcelona, Spain
2 shared publications Aline da Silva Rocha
1 shared publication- Aline da Silva Rocha
Programa de Pós-Graduação em Zootecnia, Universidade Federal da Bahia, Salvador, BA, Brasil
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Journal of Comparative Physiology B
- Vol. 196 (5) , 719-736
Carbohydrate content in the diet of red-bellied pacu (Piaractus brachypomus) and its effects on growth performance, nutrient deposition, digestive enzymes, lipogenesis, and glycolysis
This study evaluated the effects of varying dietary carbohydrate (CBH) levels on growth performance, body composition, hematological parameters, metabolism, and intestinal and hepatic enzyme activity in juvenile red-bellied pacu ( Piaractus brachypomus ). Fish (initial weight 70.25 g) were fed three times daily to apparent satiety for 45 days with diets containing 371.80–378.20 g kg –1 crude protein and 17.00-17.42 MJ kg –1 gross energy, and supplemented with 230, 260, 290, 320, or 350 g CBH kg –1 . Fish were distributed among 15 tanks (practical volume of 800 L; stocking density of 0.878 g L –1 ), with treatments replicated 3 times. Optimal growth performance, feed conversion ratio, and whole-body nutrient deposition were observed in fish fed diets containing 260–290 g CBH kg –1 . Fish fed the highest CBH level (350 g kg –1 ) exhibited reduced erythrocyte counts but increased hemoglobin concentration. Increasing dietary CBH levels resulted in higher hepatosomatic index, plasma triglyceride concentration, and liver and muscle glycogen stores, while reducing the viscerosomatic index and hepatic aspartate aminotransferase activity, with no effect on glycemia. Intermediate CBH levels (260–320 g kg –1 ) increased intestinal amylase and lipase activities but reduced alkaline protease activity. In the liver, high-CBH diets stimulated the activity of key enzymes involved in glycolysis (6-phosphofructo-1-kinase, PFK1; and pyruvate kinase, PK), the pentose phosphate pathway (6-phosphogluconate dehydrogenase, 6PGDH), and the tricarboxylic acid cycle (isocitrate dehydrogenase, ICDH), while decreasing the activity of rate-limiting enzymes in gluconeogenesis (fructose-1,6-bisphosphatase 1, FBPase1) and amino acid deamination (glutamate dehydrogenase, GDH). In conclusion, dietary CBH levels between 260 and 290 g kg –1 are recommended to optimize growth performance and enhance digestive and hematometabolical efficiency in juvenile red-bellied pacu. Exceeding this range may impair performance and welfare, highlighting the importance of precise dietary formulation in aquaculture.
- 15 September 2026
- Published by Springer Nature in Journal of Comparative Physiology B
- Vol. 196 (5) , 719-736
Open AccessCarbohydrate content in the diet of red-bellied pacu (Piaractus brachypomus) and its effects on growth performance, nutrient deposition, digestive enzymes, lipogenesis, and glycolysis
This study evaluated the effects of varying dietary carbohydrate (CBH) levels on growth performance, body composition, hematological parameters, metabolism, and intestinal and hepatic enzyme activity in juvenile red-bellied pacu ( Piaractus brachypomus ). Fish (initial weight 70.25 g) were fed three times daily to apparent satiety for 45 days with diets containing 371.80–378.20 g kg –1 crude protein and 17.00-17.42 MJ kg –1 gross energy, and supplemented with 230, 260, 290, 320, or 350 g CBH kg –1 . Fish were distributed among 15 tanks (practical volume of 800 L; stocking density of 0.878 g L –1 ), with treatments replicated 3 times. Optimal growth performance, feed conversion ratio, and whole-body nutrient deposition were observed in fish fed diets containing 260–290 g CBH kg –1 . Fish fed the highest CBH level (350 g kg –1 ) exhibited reduced erythrocyte counts but increased hemoglobin concentration. Increasing dietary CBH levels resulted in higher hepatosomatic index, plasma triglyceride concentration, and liver and muscle glycogen stores, while reducing the viscerosomatic index and hepatic aspartate aminotransferase activity, with no effect on glycemia. Intermediate CBH levels (260–320 g kg –1 ) increased intestinal amylase and lipase activities but reduced alkaline protease activity. In the liver, high-CBH diets stimulated the activity of key enzymes involved in glycolysis (6-phosphofructo-1-kinase, PFK1; and pyruvate kinase, PK), the pentose phosphate pathway (6-phosphogluconate dehydrogenase, 6PGDH), and the tricarboxylic acid cycle (isocitrate dehydrogenase, ICDH), while decreasing the activity of rate-limiting enzymes in gluconeogenesis (fructose-1,6-bisphosphatase 1, FBPase1) and amino acid deamination (glutamate dehydrogenase, GDH). In conclusion, dietary CBH levels between 260 and 290 g kg –1 are recommended to optimize growth performance and enhance digestive and hematometabolical efficiency in juvenile red-bellied pacu. Exceeding this range may impair performance and welfare, highlighting the importance of precise dietary formulation in aquaculture.
- Open Access
- 13 November 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (11) , 434
Chitosan-Mediated Expression of Caenorhabditis elegans fat-1 and fat-2 in Sparus aurata: Short-Term Effects on the Hepatic Fatty Acid Profile, Intermediary Metabolism, and Proinflammatory Factors
A single dose of chitosan-tripolyphosphate (TPP) nanoparticles carrying expression plasmids for fish codon-optimized Caenorhabditis elegans fat-1 and fat-2 was intraperitoneally administered to gilthead seabream (Sparus aurata) to stimulate the biosynthesis of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and evaluate subsequent short-term effects on liver intermediary metabolism and immunity. Seventy-two hours post-injection, the upregulation of fat-1 elevated eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and total n-3 fatty acids in the liver, while fat-2 enhanced DHA and n-3 fatty acids. Co-expression of fat-1 and fat-2 increased EPA, DHA, PUFA, and the total n-6 and n-3 LC-PUFA, while reducing plasma triglycerides. The expression of fat-1 and fat-2 suppressed hepatic lipogenesis by downregulating srebf1 and pparg, and consequently key genes in fatty acid synthesis (acaca, acacb, fasn, scd1, and fads2). In contrast, the co-expression of fat-1 and fat-2 upregulated hnf4a, chrebp, and pfkl, a rate-limiting enzyme in glycolysis. Furthermore, fat-1 and fat-2 reduced hepatic proinflammatory markers such as tnfa and nfkb1. In addition to enhancing EPA and DHA biosynthesis, promoting glycolysis, and suppressing lipogenesis, our findings suggest that the short-term expression of C. elegans fat-1 and fat-2 in the liver may also reduce inflammation and, therefore, could impact the health and growth performance of cultured fish.
- 13 November 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (11) , 434
Open AccessChitosan-Mediated Expression of Caenorhabditis elegans fat-1 and fat-2 in Sparus aurata: Short-Term Effects on the Hepatic Fatty Acid Profile, Intermediary Metabolism, and Proinflammatory Factors
A single dose of chitosan-tripolyphosphate (TPP) nanoparticles carrying expression plasmids for fish codon-optimized Caenorhabditis elegans fat-1 and fat-2 was intraperitoneally administered to gilthead seabream (Sparus aurata) to stimulate the biosynthesis of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and evaluate subsequent short-term effects on liver intermediary metabolism and immunity. Seventy-two hours post-injection, the upregulation of fat-1 elevated eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and total n-3 fatty acids in the liver, while fat-2 enhanced DHA and n-3 fatty acids. Co-expression of fat-1 and fat-2 increased EPA, DHA, PUFA, and the total n-6 and n-3 LC-PUFA, while reducing plasma triglycerides. The expression of fat-1 and fat-2 suppressed hepatic lipogenesis by downregulating srebf1 and pparg, and consequently key genes in fatty acid synthesis (acaca, acacb, fasn, scd1, and fads2). In contrast, the co-expression of fat-1 and fat-2 upregulated hnf4a, chrebp, and pfkl, a rate-limiting enzyme in glycolysis. Furthermore, fat-1 and fat-2 reduced hepatic proinflammatory markers such as tnfa and nfkb1. In addition to enhancing EPA and DHA biosynthesis, promoting glycolysis, and suppressing lipogenesis, our findings suggest that the short-term expression of C. elegans fat-1 and fat-2 in the liver may also reduce inflammation and, therefore, could impact the health and growth performance of cultured fish.
- Open Access
Bayesian Meta-Analysis: Impacts of Eating Habits and Habitats on Omega-3 Long-Chain Polyunsaturated Fatty Acid Composition and Growth in Cultured Fish
Omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) such as eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) offer protective benefits against various pathological conditions, including atherosclerosis, obesity, inflammation, and autoimmune diseases. Marine fish and seafood are the primary sources of n-3 LC-PUFAs in the human diet. However, the inclusion of fish oil in aquafeeds is declining due to limited availability, fluctuating prices, sustainability concerns, and replacement with vegetable oils. While comprehensive narrative reviews on the impact of substituting fish oil with vegetable oil in aquafeeds exist, quantitative studies are relatively scarce and mainly focused on comparing the source of vegetable oils. Herein, we employed, for the first time, a Bayesian meta-analysis approach, collecting research data from 81 articles to quantitatively analyze the effects of dietary n-3 LC-PUFA levels on the n-3 LC-PUFA composition and growth performance in cultured fish. Our findings indicate that with the exception of herbivorous fish, dietary n-3 LC-PUFA levels significantly affect the EPA and DHA levels in the livers and muscles of carnivorous, omnivorous, freshwater, and marine fish. Additionally, the growths of freshwater and herbivorous fish were less affected by changes in dietary n-3 LC-PUFA levels compared to that of carnivorous and marine fish.
Open AccessBayesian Meta-Analysis: Impacts of Eating Habits and Habitats on Omega-3 Long-Chain Polyunsaturated Fatty Acid Composition and Growth in Cultured Fish
Omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) such as eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) offer protective benefits against various pathological conditions, including atherosclerosis, obesity, inflammation, and autoimmune diseases. Marine fish and seafood are the primary sources of n-3 LC-PUFAs in the human diet. However, the inclusion of fish oil in aquafeeds is declining due to limited availability, fluctuating prices, sustainability concerns, and replacement with vegetable oils. While comprehensive narrative reviews on the impact of substituting fish oil with vegetable oil in aquafeeds exist, quantitative studies are relatively scarce and mainly focused on comparing the source of vegetable oils. Herein, we employed, for the first time, a Bayesian meta-analysis approach, collecting research data from 81 articles to quantitatively analyze the effects of dietary n-3 LC-PUFA levels on the n-3 LC-PUFA composition and growth performance in cultured fish. Our findings indicate that with the exception of herbivorous fish, dietary n-3 LC-PUFA levels significantly affect the EPA and DHA levels in the livers and muscles of carnivorous, omnivorous, freshwater, and marine fish. Additionally, the growths of freshwater and herbivorous fish were less affected by changes in dietary n-3 LC-PUFA levels compared to that of carnivorous and marine fish.
- Open Access
- 26 October 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (11) , 562
Chitosan-Based Sustained Expression of Sterol Regulatory Element-Binding Protein 1a Stimulates Hepatic Glucose Oxidation and Growth in Sparus aurata
The administration of a single dose of chitosan nanoparticles driving the expression of sterol regulatory element-binding protein 1a (SREBP1a) was recently associated with the enhanced conversion of carbohydrates into lipids. To address the effects of the long-lasting expression of SREBP1a on the growth and liver intermediary metabolism of carnivorous fish, chitosan-tripolyphosphate (TPP) nanoparticles complexed with a plasmid expressing the N terminal active domain of hamster SREBP1a (pSG5-SREBP1a) were injected intraperitoneally every 4 weeks (three doses in total) to gilthead sea bream (Sparus aurata) fed high-protein–low-carbohydrate and low-protein–high-carbohydrate diets. Following 70 days of treatment, chitosan-TPP-pSG5-SREBP1a nanoparticles led to the sustained upregulation of SREBP1a in the liver of S. aurata. Independently of the diet, SREBP1a overexpression significantly increased their weight gain, specific growth rate, and protein efficiency ratio but decreased their feed conversion ratio. In agreement with an improved conversion of dietary carbohydrates into lipids, SREBP1a expression increased serum triglycerides and cholesterol as well as hepatic glucose oxidation via glycolysis and the pentose phosphate pathway, while not affecting gluconeogenesis and transamination. Our findings support that the periodical administration of chitosan-TPP-DNA nanoparticles to overexpress SREBP1a in the liver enhanced the growth performance of S. aurata through a mechanism that enabled protein sparing by enhancing dietary carbohydrate metabolisation.
- 26 October 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (11) , 562
Open AccessChitosan-Based Sustained Expression of Sterol Regulatory Element-Binding Protein 1a Stimulates Hepatic Glucose Oxidation and Growth in Sparus aurata
The administration of a single dose of chitosan nanoparticles driving the expression of sterol regulatory element-binding protein 1a (SREBP1a) was recently associated with the enhanced conversion of carbohydrates into lipids. To address the effects of the long-lasting expression of SREBP1a on the growth and liver intermediary metabolism of carnivorous fish, chitosan-tripolyphosphate (TPP) nanoparticles complexed with a plasmid expressing the N terminal active domain of hamster SREBP1a (pSG5-SREBP1a) were injected intraperitoneally every 4 weeks (three doses in total) to gilthead sea bream (Sparus aurata) fed high-protein–low-carbohydrate and low-protein–high-carbohydrate diets. Following 70 days of treatment, chitosan-TPP-pSG5-SREBP1a nanoparticles led to the sustained upregulation of SREBP1a in the liver of S. aurata. Independently of the diet, SREBP1a overexpression significantly increased their weight gain, specific growth rate, and protein efficiency ratio but decreased their feed conversion ratio. In agreement with an improved conversion of dietary carbohydrates into lipids, SREBP1a expression increased serum triglycerides and cholesterol as well as hepatic glucose oxidation via glycolysis and the pentose phosphate pathway, while not affecting gluconeogenesis and transamination. Our findings support that the periodical administration of chitosan-TPP-DNA nanoparticles to overexpress SREBP1a in the liver enhanced the growth performance of S. aurata through a mechanism that enabled protein sparing by enhancing dietary carbohydrate metabolisation.
- Open Access
Chitosan-Based Drug Delivery System: Applications in Fish Biotechnology
Chitosan is increasingly used for safe nucleic acid delivery in gene therapy studies, due to well-known properties such as bioadhesion, low toxicity, biodegradability and biocompatibility. Furthermore, chitosan derivatization can be easily performed to improve the solubility and stability of chitosan–nucleic acid polyplexes, and enhance efficient target cell drug delivery, cell uptake, intracellular endosomal escape, unpacking and nuclear import of expression plasmids. As in other fields, chitosan is a promising drug delivery vector with great potential for the fish farming industry. This review highlights state-of-the-art assays using chitosan-based methodologies for delivering nucleic acids into cells, and focuses attention on recent advances in chitosan-mediated gene delivery for fish biotechnology applications. The efficiency of chitosan for gene therapy studies in fish biotechnology is discussed in fields such as fish vaccination against bacterial and viral infection, control of gonadal development and gene overexpression and silencing for overcoming metabolic limitations, such as dependence on protein-rich diets and the low glucose tolerance of farmed fish. Finally, challenges and perspectives on the future developments of chitosan-based gene delivery in fish are also discussed.
Open AccessChitosan-Based Drug Delivery System: Applications in Fish Biotechnology
Chitosan is increasingly used for safe nucleic acid delivery in gene therapy studies, due to well-known properties such as bioadhesion, low toxicity, biodegradability and biocompatibility. Furthermore, chitosan derivatization can be easily performed to improve the solubility and stability of chitosan–nucleic acid polyplexes, and enhance efficient target cell drug delivery, cell uptake, intracellular endosomal escape, unpacking and nuclear import of expression plasmids. As in other fields, chitosan is a promising drug delivery vector with great potential for the fish farming industry. This review highlights state-of-the-art assays using chitosan-based methodologies for delivering nucleic acids into cells, and focuses attention on recent advances in chitosan-mediated gene delivery for fish biotechnology applications. The efficiency of chitosan for gene therapy studies in fish biotechnology is discussed in fields such as fish vaccination against bacterial and viral infection, control of gonadal development and gene overexpression and silencing for overcoming metabolic limitations, such as dependence on protein-rich diets and the low glucose tolerance of farmed fish. Finally, challenges and perspectives on the future developments of chitosan-based gene delivery in fish are also discussed.